Friday, February 18, 2022
COVID-19 Monoclonal Antibodies: FDA Authorized Bebtelovimab
On February 11, the FDA authorized the emergency use (PDF) of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply:
- They have a positive COVID-19 test result
- They’re at high-risk for progression to severe COVID-19
- Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them
CMS created new codes, effective February 11:
- Long descriptor: Injection, bebtelovimab, 175 mg
- Short descriptor: Bebtelovimab 175
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring
- Short Descriptor: Bebtelovimab injection
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
- Short Descriptor: Bebtelovimab injection home
Visit the COVID-19 Monoclonal Antibodies webpage for more information.
Report a problem viewing this newsletter.
Subscribe to the MLN Connects® newsletter. Previous issues are available in the archive.
This newsletter is current as of the issue date. View the complete disclaimer.
Follow the MLN on Twitter #CMSMLN, and visit us on YouTube.
The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health and Human Services (HHS).